ARS Pharmaceuticals (SPRY) Capital Expenditures (2020 - 2025)
ARS Pharmaceuticals (SPRY) posted Capital Expenditures of -$5.5 million for Q3 2025, down 195.7% sequentially from $5.8 million in Q2 2025, and down 2215.33% YoY from $261000.0 in Q3 2024.
ARS Pharmaceuticals (SPRY) Capital Expenditures (2020 - 2025) Analysis & Trends
ARS Pharmaceuticals has reported Capital Expenditures for 6 years, with the latest figure at -$5.5 million in Q3 2025.
- Quarterly Capital Expenditures fell 2215.33% year-over-year to -$5.5 million in Q3 2025, while the trailing twelve-month figure through Mar 2026 was $248000.0 (down 56.57% YoY) and the FY2025 annual result came in at $339000.0, down 39.79% from the prior year.
- Capital Expenditures eased to -$5.5 million in Q3 2025 per SPRY's latest filing, from $5.8 million in the prior quarter.
- Over five years, Capital Expenditures peaked at $5.8 million in Q2 2025 and troughed at -$5.5 million in Q3 2025.
- A 5-year average of $70888.9 and a median of $83500.0 in 2023 frame the typical range for Capital Expenditures.
- The sharpest annual moves came in 2021 and 2025: Capital Expenditures surged 13900.0% in 2021, then sank 2215.33% in 2025.
- Over 5 years, Capital Expenditures stood at -$822000.0 in 2021, then jumped by 115.33% to $126000.0 in 2022, then plunged by 33.33% to $84000.0 in 2023, then soared by 259.52% to $302000.0 in 2024, then tumbled by 1928.15% to -$5.5 million in 2025.
- According to Business Quant data, Capital Expenditures over the past three periods registered -$5.5 million, $5.8 million, and $91000.0 for Q3 2025, Q2 2025, and Q1 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.29 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.02 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 572,662.23 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 251.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 34.68 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.26 Mn |
| 10 | ARS Pharmaceuticals | 561.88 Mn | 418.03 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -5.52 Mn |
| Sep 30, 2025 | -5.52 Mn |
| Jun 30, 2025 | 5.77 Mn |
| Jun 30, 2025 | 5.77 Mn |
| Mar 31, 2025 | 91,000.00 |
| Mar 31, 2025 | 91,000.00 |
| Dec 31, 2024 | 302,000.00 |
| Dec 31, 2024 | 302,000.00 |
| Sep 30, 2024 | 261,000.00 |
| Sep 30, 2024 | 261,000.00 |
| Jun 30, 2024 | -83,000.00 |
| Jun 30, 2024 | -83,000.00 |
| Mar 31, 2024 | 83,000.00 |
| Mar 31, 2024 | 83,000.00 |
| Dec 31, 2023 | 84,000.00 |
| Dec 31, 2023 | 84,000.00 |
| Jun 30, 2023 | -102,000.00 |
| Jun 30, 2023 | -102,000.00 |
| Mar 31, 2023 | 193,000.00 |
| Mar 31, 2023 | 193,000.00 |